2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 483

Can a Single Question on Functional Impairments Facilitate the Diagnosis of Early Inflammatory Arthritis? A Cross-Sectional Derivation and Validation Study in Two Early Arthritis Recognition Clinics
Abstract Number: 1194

Can an MDHAQ (Multidimensional Health Assessment Questionnaire) 60-Symptom Checklist to Monitor Early Medication Outcomes (MDHAQ/MEMO60) Detect Adverse Events of High-Risk Medications?
Abstract Number: 2505

Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina
Abstract Number: 613

Can Fecal Calprotectin Predict Future Development of Inflammatory Bowel Disease in Axial Spondyloarthritis Patients? – TReasure Real-Life Preliminary Data
Abstract Number: 790

Can High ANA Titre Combined with Clinical Features Predict Developing Autoimmune Conditions in Children?
Abstract Number: 1250

Can Patient-Reported Outcomes and Disease Activity Scores Predict Patient Acceptable Symptom State in Adult-Onset Still’s Disease?
Abstract Number: 283

Can Synovial Hypertrophy in the Feet Without Doppler Change During Treatment – Results from a Longitudinal Study of Rheumatoid Arthritis Patients Initiating Biological DMARD
Abstract Number: 1570

Can the Montreal Cognitive Assessment (MoCA) Improve the Automated Neuropsychological Assessment Metrics (ANAM) Performance in Screening for Cognitive Impairment in Lupus Patients?
Abstract Number: 1714

Can We Predict Early Relapses in Adult IgA Vasculitis?
Abstract Number: 2227

Can We Predict Hypophosphatasia-Mutation Result Based on Alkaline Phosphatase Serum Levels?
Abstract Number: 802

Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial
Abstract Number: 2785

Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications
Abstract Number: 1082

Cancer Risk in Patients with Ankylosing Spondylitis: A Nationwide Population-based Dynamic Cohort Study from Korea
Abstract Number: 2929

Cannabis Use Among Patients in a Large US Rheumatic Disease Registry
Abstract Number: 1683

Cardiac Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss): Initial Manifestations and Outcomes Based on Data from a Monocenter Patient Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].